Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Urinary Tract Infection

  Free Subscription


Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 33 articles:
HTML format



Single Articles


    December 2023
  1. SHI H, Zeng L
    Comment on: Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Dec 9:107059.
    PubMed    


    November 2023
  2. KIM C, Choi YH, Choi JY, Choi HJ, et al
    Translation of Machine Learning-Based Prediction Algorithms to Personalised Empiric Antibiotic Selection: A Population-Based Cohort Study.
    Int J Antimicrob Agents. 2023;62:106966.
    PubMed     Abstract available


    September 2023
  3. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    PubMed     Abstract available


  4. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    PubMed     Abstract available


    April 2023
  5. HUNG KC, Tsai WW, Hsu CW, Lai CC, et al
    Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Apr 24:106830.
    PubMed     Abstract available


  6. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    PubMed     Abstract available


    March 2023
  7. DE OCA JEM, Veve MP, Zervos MJ, Kenney RM, et al
    Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections.
    Int J Antimicrob Agents. 2023 Mar 31:106800.
    PubMed     Abstract available


    August 2022
  8. BELMONT-MONROY L, Ribas-Aparicio RM, Gonzalez-Villalobos E, Perez-Ramos JA, et al
    Molecular typification of Escherichia coli from community-acquired urinary tract infections in Mexico.
    Int J Antimicrob Agents. 2022 Aug 26:106667.
    PubMed     Abstract available


    April 2022
  9. FOSSE PE, Brinkman KM, Brink HM, Conner CE, et al
    Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents.
    Int J Antimicrob Agents. 2022;59:106560.
    PubMed     Abstract available


    March 2022
  10. TUTONE M, Johansen TEB, Cai T, Mushtaq S, et al
    SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Int J Antimicrob Agents. 2022 Mar 17:106574.
    PubMed     Abstract available


    January 2022
  11. GAMBLE KC, Rose DT, Sapozhnikov J
    Intravenous to Oral Antibiotics Versus Intravenous Antibiotics: A Step-Up or a Step-Down for Extended Spectrum Beta-Lactamase Producing Urinary Tract Infections Without Concomitant Bacteremia?
    Int J Antimicrob Agents. 2022 Jan 26:106541.
    PubMed     Abstract available


  12. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available


  13. JEAN SS, Lu MC, Ho MW, Ko WC, et al
    Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdomi
    Int J Antimicrob Agents. 2022 Jan 20:106521.
    PubMed     Abstract available


    July 2021
  14. ZHANG H, Liang B, Wang J, Cai Y, et al
    Non-carbapenem beta-lactam/beta-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review.
    Int J Antimicrob Agents. 2021 Jul 30:106410.
    PubMed     Abstract available


    May 2021
  15. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available


    April 2021
  16. BIRRELL MT, Horne K, Rogers BA
    Potential interventions for an antimicrobial stewardship bundle for Escherichia coli bacteraemia.
    Int J Antimicrob Agents. 2021;57:106301.
    PubMed     Abstract available


    August 2020
  17. SEO H, Lee SC, Chung H, Ra SH, et al
    Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Int J Antimicrob Agents. 2020 Aug 2:106126.
    PubMed     Abstract available


    July 2020
  18. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available


  19. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available


    June 2020
  20. PARSONSON F, Legg A, Halford M, McCarthy K, et al
    Contemporaneous management of ampicillin infusions in the outpatient setting through the use of therapeutic drug monitoring.
    Int J Antimicrob Agents. 2020;55:105975.
    PubMed     Abstract available


    May 2020
  21. WANG T, Wu G, Wang J, Cui Y, et al
    Comparison of Single-dose Fosfomycin Tromethamine and Other Antibiotics for Lower Uncomplicated Urinary Tract Infection in Women and Asymptomatic Bacteriuria in Pregnant Women:a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2020 May 14:106018.
    PubMed     Abstract available


    April 2020
  22. NABOKA YL, Mavzyiutov AR, Kogan MI, Gudima IA, et al
    Does Escherichia coli have pathogenic potential at low level bacteriuria in recurrent, uncomplicated urinary tract infections?
    Int J Antimicrob Agents. 2020 Apr 21:105983.
    PubMed     Abstract available


  23. CAI T, Palagin I, Brunelli R, Cipelli R, et al
    Office-based approach to urinary tract infections on 50000 patients: results from the REWIND study.
    Int J Antimicrob Agents. 2020 Apr 20:105966.
    PubMed     Abstract available


    March 2020
  24. GARCIA-FERNANDEZ S, Garcia-Castillo M, Melo-Cristino J, Pinto MF, et al
    In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    Int J Antimicrob Agents. 2020;55:105887.
    PubMed     Abstract available


  25. MARAOLO AE, Mazzitelli M, Trecarichi EM, Buonomo AR, et al
    Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Int J Antimicrob Agents. 2020;55:105891.
    PubMed     Abstract available


    January 2020
  26. TUMBARELLO M, Raffaelli F, Peghin M, Losito AR, et al
    Characterisation and risk-factor profiling of P. aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
    Int J Antimicrob Agents. 2020 Jan 10:105900.
    PubMed     Abstract available


  27. DA SILVA BNM, Faria AR, de Souza SDSR, Colodette SS, et al
    Expression of VanA-type vancomycin resistance in a clinical isolate of Enterococcus faecium showing insertion of IS19 in the vanS gene.
    Int J Antimicrob Agents. 2020 Jan 10:105897.
    PubMed     Abstract available


    November 2019
  28. CHENG IL, Chen YH, Lai CC, Tang HJ, et al
    The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and urinary tract infections-A meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2019 Nov 28. pii: S0924-8579(19)30329.
    PubMed     Abstract available


  29. ZYKOV IN, Frimodt-Moller N, Smabrekke L, Sundsfjord A, et al
    The efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Int J Antimicrob Agents. 2019 Nov 23. pii: S0924-8579(19)30322.
    PubMed     Abstract available


  30. ROY SM, Riley MA
    Evaluation of the potential of colicins to prevent extraluminal contamination of urinary catheters by Escherichia coli.
    Int J Antimicrob Agents. 2019;54:619-625.
    PubMed     Abstract available


    August 2019
  31. XU Q, Jiang J, Zhu Z, Xu T, et al
    Efflux pumps AcrAB and OqxAB contribute to nitrofurantoin resistance in an uropathogenic Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2019;54:223-227.
    PubMed     Abstract available


    July 2019
  32. KARLOWSKY JA, Lagace-Wiens PRS, Adam HJ, Baxter MR, et al
    In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.
    Int J Antimicrob Agents. 2019;54:62-68.
    PubMed     Abstract available


    March 2019
  33. GOLDSTEIN E, MacFadden DR, Karaca Z, Steiner CA, et al
    Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states.
    Int J Antimicrob Agents. 2019 Mar 6. pii: S0924-8579(19)30056.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Urinary Tract Infection is free of charge.